NCT00762424 (Flowmax) is a NA clinical trial of Flowmax in Kidney Stone, sponsored by WellSpan Health.

Who is sponsoring NCT00762424?

NCT00762424 is sponsored by WellSpan Health.

What drugs are being tested in NCT00762424?

Interventions in NCT00762424: Flowmax, placebo.

What condition does NCT00762424 study?

NCT00762424 studies Kidney Stone.

Is NCT00762424 still recruiting?

NCT00762424 is currently completed. Last updated 16 December 2014.

Are results published for NCT00762424?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2014-12-16 · How we verify

NCT00762424: Flowmax

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis

Completed NA Results posted Last updated 16 December 2014

What this trial tests

NA trial testing Flowmax in Kidney Stone in 53 participants. Completed in 1 January 2011.

Timeline

1 June 2007

Primary endpoint
1 January 2011

1 January 2011

Quick facts

Lead sponsor	WellSpan Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	53
Start date	1 June 2007
Primary completion	1 January 2011
Estimated completion	1 January 2011
Sites	1 location across United States

Drugs / interventions tested

Flowmax — full drug profile →
placebo

Conditions studied

Kidney Stone — all drugs for Kidney Stone →

Sponsor

WellSpan Health — full company profile →

Who can join

18 and older, any sex, with Kidney Stone. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time of Stone Passage
Time frame: 10 Days
Upon discharge, patient must be able to take the medication for 10 days and strain his/her urine. Patient must log the date and time of stone passage, if known.

Sponsor's own description

Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in the non-Emergency Department setting. This study will compare Tamsulosin 0.4 mg with placebo in regards to rate and time of stone passing and will also look at amount of pain. The purpose of this study is to compare the usefulness of Tamsulosin versus placebo on time to stone passage and pain relief in Emergency Department patients with kidney stones.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Kidney Stone

Currently open trials in the same condition.

NCT06944223 — Oxalate and Citrate in Humans - Response to Citrate · NA · recruiting
NCT07071948 — A Single-Center Clinical Study on the Efficacy and Safety of VISOR · NA · recruiting
NCT06576661 — Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Be · NA · recruiting
NCT06210009 — Effect of a DASH-Style Diet on Urinary Risk Factors for Kidney Stone Disease · NA · recruiting
NCT07238803 — Outcomes of Using FANS With FURS in TTT of Lower Calyceal Stones. · NA · recruiting

Other WellSpan Health trials

Trials by the same sponsor.

NCT06507670 — Point of Care Ultrasound for the Detection of Esophageal Food Bolus · recruiting
NCT06779526 — Effect of Four-Week Wellness Program on Work Engagement Burnout and Sleep in a Healthcare Organization (WEBS) · NA · completed
NCT05748366 — Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures · NA · recruiting
NCT05538273 — Optimal Management of Urinary Catheter in Gyn Onc · withdrawn
NCT05082246 — Impact of Complimentary and Alternative Practices on Patient Wellbeing During Rehabilitation · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00762424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by WellSpan Health
Last refreshed: 16 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00762424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing